^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    vilastobart (XTX101)

    i
    Other names: XTX101, XTX 101, XTX-101
    Company:
    Xilio Therap
    Drug class:
    CTLA4 inhibitor
    Related drugs:
    4ms
    Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=136, Recruiting, Xilio Development, Inc. | N=96 --> 136
    Enrollment change • Combination therapy • Metastases
    |
    Tecentriq (atezolizumab) • vilastobart (XTX101)
    10ms
    XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer. (PubMed, J Immunother Cancer)
    These data demonstrate that XTX101 retains the full potency of an Fc-enhanced CTLA-4 antagonist within the TME while minimizing the activity in non-tumor tissue, supporting the further evaluation of XTX101 in clinical studies.
    PK/PD data • Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Yervoy (ipilimumab) • vilastobart (XTX101)